Skip to content

50% of Joint Disease Patients Could Benefit: New Licensing Agreements Signed

Enveric Biosciences, through its subsidiary Akos Biosciences, has entered into two licensing agreements with Restoration Biologics LLC. These agreements focus on the development of treatments for joint diseases using Akos’s cannabinoid-COX-2 conjugate compounds. The agreements aim to leverage these compounds for pharmaceutical applications, potentially benefiting a significant portion of the population suffering from joint issues. The specifics of the financial terms of the deal were not disclosed. However, the collaboration is set to explore new therapeutic avenues, potentially impacting the lives of many patients.

Source: seekingalpha.com

Related Videos